Epilepsy (partial) - retigabine (adjuvant) (TA232)
Fast, easy summary view of NICE guidance on 'epilepsy'
Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
NICE recommends retigabine as a possible add-on (also known as adjunctive) treatment for partial onset seizures with or without secondary generalisation in some people with epilepsy (see below).
Who can have retigabine?
If you are 18 or over, you should be able to have retigabine as an add-on treatment for partial onset seizures if you have tried drugs called carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate and topiramate but they have not worked well or you had a bad reaction to them.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended retigabine in these circumstances because it works as well and costs about the same as other treatments that are available on the NHS after carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate and topiramate have already been tried.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: epilepsy
- None found
This page was last updated: 31 May 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA232 Retigabine fel triniaeth ychwanegol ar gyfer trawiadau rhannol yn ymwneud ag epilepsi: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.